Ziprasidone in the Psychosis Prodrome

• Status: Completed
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Treatments: Ziprasidone

Criteria

Inclusion Criteria:

• SIPS criteria for psychosis prodrome

• clinically referred

Exclusion Criteria:

• prolonged QTc

• history of syncope